A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma
Introduction
Existing chemotherapeutic options for patients with unresectable metastatic or locally advanced adenocarcinoma of the exocrine pancreas are of limited value. In general, monotherapy with traditional agents such as 5-fluorouracil (5-FU) has resulted in variable response rates (usually less than 10%) and short response durations, and there is scant evidence to suggest that conventional combination therapy offers additional benefit 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12. Similarly, modulation of 5-FU with agents such as leucovorin and interferon-α seems to offer little therapeutic advantage over 5-FU alone (although a response rate of 38% was reported recently for the combination of 5-FU, leucovorin, interferon-α-2b and cisplatin) and is associated with considerable toxicity 13, 14, 15, 16, 17, 18.
Despite the discouraging results achieved with existing therapies, trials comparing best supportive care and chemotherapy suggest that chemotherapy does have a positive effect on survival and quality of life 19, 20. Recent research has continued to focus therefore on the development of new active drugs suitable for use as first-line single agents in the treatment of metastatic or locally advanced pancreatic cancer.
One new agent of interest is docetaxel (Taxotere®; Rhône-Poulenc Rorer, Antony, France), a taxoid obtained by hemisynthesis from an inactive precursor extracted from the needles of the European yew, Taxus baccata. Taxoids enhance microtubule assembly and inhibit the depolymerisation of tubulin, thereby promoting the formation of stable, intracellular bundles of microtubules, which disrupt cell replication 21, 22, 23, 24. This mode of action contrasts with those of other spindle poisons in clinical use, such as the vinca alkaloids, which inhibit the polymerisation of tubulin into functional microtubules [25].
This study was performed to evaluate the efficacy of docetaxel as first-line chemotherapy for patients with unresectable metastatic or locally advanced adenocarcinoma of the pancreas, as part of a phase II clinical trial programme. The study also aimed to further characterise the safety and pharmacokinetic profiles of docetaxel in this group of patients.
Section snippets
Eligibility
Men and women aged 18–75 years, with histologically or cytologically proven metastatic or locally advanced pancreatic adenocarcinoma, at least one bidimensionally measurable target lesion, a World Health Organization (WHO) performance status of 0–2, adequate haematological and renal functions, a total bilirubin of ⩽1.25×upper normal limit, aspartate aminotransferase ⩽2×upper normal limit and a life expectancy of at least 12 weeks, were eligible for recruitment into the study.
Specific criteria
Patient disposition and characteristics
All 43 patients (26 males, 17 females) enrolled in the study received at least one docetaxel infusion: 1 patient was not eligible due to active uncontrolled infection at study entry. All patients were evaluable for safety. Baseline elevated concentrations of hepatic enzymes and/or bilirubin above the cut-off defined by the protocol were reported in 5 patients. However, as these abnormalities could be related to the disease, all these patients were included and considered eligible. 3 patients
Discussion
This multicentre, phase II study has shown that docetaxel (100 mg/m2/3 weeks) is an active agent for the treatment of patients with pancreatic adenocarcinoma. Docetaxel produced an encouragingly high response rate of 19% in evaluable patients with metastatic disease and a response rate of 15% in the overall population with a median duration of response of 5.1 (range 3.1–7.2) months. Docetaxel also controlled tumour growth for a median duration of 4.4 months in 6 out of the 9 patients with
Acknowledgements
This work was supported by a grant from Rhône-Poulenc Rorer, Antony, France. We thank Dr R. Pazdur from MD Anderson Cancer Center, Houston, USA, Dr Wils and Dr Schlange from St Laurentius Ziekenhuis, The Netherlands for diagnostic reassessment of our series of cases, René Bruno and Jean-Claude Vergniol for their contributions to the pharmacokinetic analysis and Eric Le Bras for his contribution to the statistical analysis. We thank also the nurses of Unité La Grange, Institut Gustave Roussy,
References (42)
- et al.
Phase II study of cisplatin and 120-hour continuous infusion of 5-fluorouracil in patients with advanced pancreatic adenocarcinoma
Ann. Oncol.
(1993) - et al.
Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer
Ann. Oncol.
(1996) - et al.
Determination of taxotere in human plasma by a semi-automated high-performance liquid chromatographic method
J. Chromatogr.
(1992) Optimal two-stage design for phase II clinical trials
Control. Clin. Trials
(1989)- et al.
Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study
Ann. Oncol.
(1995) - et al.
A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer
Ann. Oncol.
(1996) - et al.
Activity of cisplatin in adenocarcinoma of the pancreas
Eur. J. Cancer
(1993) - Evans DB, Abbruzzese JL, Rich TA. Cancer of the pancreas. In DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer:...
- Smalley SR, Macdonald JS. Pancreatic cancer. In Calabresi P, Schein PS, eds. Medical Oncology, 2nd edn. McGraw-Hill,...
The use of chemotherapy in the treatment of advanced gastric and pancreas cancer
Semin. Oncol.
(1994)
A clinical study of fluorouracil
Surg. Gynecol. Obstet.
Use of 5-fluorouracil in disseminated solid neoplasms
Ann. Surg.
Descriptive epidemiology of cancer of the pancreas
Bull. Cancer (Paris)
A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin
Cancer
Phase II studies of drug combinations in advanced pancreatic carcinomafluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil
J. Clin. Oncol.
5-fluorouracil, adriamycin, and mitomycin-C (FAM) chemotherapy for advanced adenocarcinoma of the pancreas
Cancer
Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM)
Cancer
Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer
Cancer
Treatment of advanced pancreatic adenocarcinoma with 5-FU, leucovorin, interferon-alpha-2b, and cisplatin
Am. J. Clin. Oncol.
Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma
J. Clin. Oncol.
Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreasresults of a phase II trial
J. Clin. Oncol.
Cited by (101)
A novel view of the separate and simultaneous binding effects of docetaxel and anastrozole with calf thymus DNA: Experimental and in silico approaches
2020, Spectrochimica Acta - Part A: Molecular and Biomolecular SpectroscopyCitation Excerpt :Cells are arrested at the G2/M transition, which causes failed cell division and cytotoxicity [32]. DO is apparently a more potent antimicrotubular agent than paclitaxel in vitro [33], which has been also observed to be active in a broad range of tumors including carcinomas of lung, breast, bladder, pancreas, head and neck, and ovary [34,35]. The efficacy of DO 100 mg/m2 as a monotherapy or in combination with other cytotoxic agents has been confirmed in phase III trials throughout the metastatic breast cancer patients [36–38] (see Scheme 2).
Tumour-stroma interactions in pancreatic ductal adenocarcinoma: Rationale and current evidence for new therapeutic strategies
2014, Cancer Treatment ReviewsCitation Excerpt :Evidence to support the anticancer activity of nab-paclitaxel in pancreatic cancer may also be derived from clinical studies of the older taxane, docetaxel. Indeed, several Phase II studies and retrospective analyses have all shown that treatment with docetaxel, as part of a multidrug regimen75–81 or as monotherapy,82 is associated with some clinical benefit. To date, three Phase I/II clinical studies evaluating nab-paclitaxel in patients with advanced/metastatic pancreatic cancer have been completed.
Cost-effectiveness of gene-expression profiling for tumor-site origin
2013, Value in HealthMedical treatment of pancreatic cancer: New hopes after 10years of gemcitabine
2011, Clinics and Research in Hepatology and GastroenterologyCitation Excerpt :Pemetrexed and multridrug regimen combining cisplatin, epirubicin, fluorouracil have been evaluated too in association with gemcitabine in phase III trials without any improvement of OS [36,37]. Docetaxel has been evaluated at first only then in association with the gemcitabine in several phase II studies, RR were 12 to 20% and OS 4.5 to 9 months [38–42]. A meta-analysis pooled the data of randomised trials, which compared gemcitabine to gemcitabine-based combination chemotherapy.
A phase 1b study of OXIRI in pancreatic adenocarcinoma patients and its immunomodulatory effects
2022, International Journal of Cancer